Global Hepcidin

Hepcidin Comprehensive Study by Type (DS-79182026, M-009, PRS-080, PTG-300, Others), Application (Acute Inflammation, Anemia, Iron Deficiency Anemia, Sickle Cell Disease, Others), End-Use (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Specialty Clinics) Players and Region - Global Market Outlook to 2030

Hepcidin Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Hepcidin is a protein that is encoded by the HAMP gene in humans. In mammals, hepcidin is a central regulator of iron absorption into the bloodstream. Because of iron trapping within macrophages and liver cells, as well as reduced gut iron absorption, serum iron drops in conditions where hepcidin levels are abnormally high, such as inflammation. This usually results in anaemia due to a lack of serum iron required for the production of red blood cells. Iron overload occurs when the hepcidin level is abnormally low, as in hemochromatosis, due to increased ferroportin-mediated iron efflux from storage and increased gut iron absorption. Patients who are unable to consume oral iron or who have been diagnosed with increasing anaemia after taking sufficient doses of oral iron supplements are usually given iron therapy. Regulatory authorities are approving a large number of intravenous iron supplementation products, which will likely push the market in the future. The increasing number of product approvals for iron deficiency anaemia therapy are expected to be significant market contributors.This growth is primarily driven by Rising the Incidence of Anemia .

AttributesDetails
Study Period2018-2030
Base Year2023
Forecast Period2024-2030
Volume UnitN
Value UnitUSD (Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


The Biotechnology sector in the region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Allergen PLC (Ireland), AMAG Pharmaceuticals Inc. (United States), Keryx Biopharmaceuticals Inc. (United States), Luitpold Pharmaceuticals Inc. (United States), Pieris Pharmaceuticals Inc. (United States), Sanofi Aventis (France), Janssen Pharmaceuticals, Inc. (United States), Pfizer Inc. (United States), Rockwell Medical (United States) and F. Hoffmann-La Roche Ltd (Switzerland), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.

Influencing Trend:
High Prevalence of Chronic Diseases and Increase in Technological Advancement in Healthcare Sector

Market Growth Drivers:
Rising the Incidence of Anemia, Unhealthy Lifestyle and Increase in Kidney Diseases

Challenges:
Stringent Regulatory Guidelines

Restraints:
High Cost of Treatment and Poor Absorption Of Drugs Especially Intravenous Iron and the Side Effects Associated with the Treatment

Opportunities:
Increase in Healthcare Expenditure and Increased Investment in R&D

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mainly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the market's growth. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Data Sources of Hepcidin Market Study

Primary Collection: InMail, LinkedIn Groups, Survey Monkey, Google, and Other professional Forums are some of the mediums utilized to gather primary data through key industry participants and appointees, subject-matter experts, C-level executives of Hepcidin Industry, among others including independent industry consultants, experts, to obtain and verify critical qualitative commentary and opinion and quantitative statistics, to assess future market prospects.

The primary interviews and data collected as per the below protocols:
• By Designation: C-Level, D-Level, Others
• By Company Type: Tier 1, Tier 2, Tier 3

Secondary Data Sources such as Annual reports, Press releases, Analyst meetings, Conference calls, Investor presentations, Management statements, and SEC filings of Hepcidin players along with Regulatory Sites, Association, World bank, etc were used as sources secondary set of data.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Hepcidin Study Sheds Light on
— The Hepcidin Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Hepcidin industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Hepcidin industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • DS-79182026
  • M-009
  • PRS-080
  • PTG-300
  • Others
By Application
  • Acute Inflammation
  • Anemia
  • Iron Deficiency Anemia
  • Sickle Cell Disease
  • Others
By End-Use
  • Hospitals
  • Ambulatory Surgical Centers
  • Diagnostic Centers
  • Specialty Clinics

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising the Incidence of Anemia
      • 3.2.2. Unhealthy Lifestyle
      • 3.2.3. Increase in Kidney Diseases
    • 3.3. Market Challenges
      • 3.3.1. Stringent Regulatory Guidelines
    • 3.4. Market Trends
      • 3.4.1. High Prevalence of Chronic Diseases
      • 3.4.2. Increase in Technological Advancement in Healthcare Sector
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hepcidin, by Type, Application, End-Use and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Hepcidin (Value)
      • 5.2.1. Global Hepcidin by: Type (Value)
        • 5.2.1.1. DS-79182026
        • 5.2.1.2. M-009
        • 5.2.1.3. PRS-080
        • 5.2.1.4. PTG-300
        • 5.2.1.5. Others
      • 5.2.2. Global Hepcidin by: Application (Value)
        • 5.2.2.1. Acute Inflammation
        • 5.2.2.2. Anemia
        • 5.2.2.3. Iron Deficiency Anemia
        • 5.2.2.4. Sickle Cell Disease
        • 5.2.2.5. Others
      • 5.2.3. Global Hepcidin by: End-Use (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Ambulatory Surgical Centers
        • 5.2.3.3. Diagnostic Centers
        • 5.2.3.4. Specialty Clinics
      • 5.2.4. Global Hepcidin Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Hepcidin: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Allergen PLC (Ireland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. AMAG Pharmaceuticals Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Keryx Biopharmaceuticals Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Luitpold Pharmaceuticals Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pieris Pharmaceuticals Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sanofi Aventis (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Janssen Pharmaceuticals, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Pfizer Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Rockwell Medical (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Hepcidin Sale, by Type, Application, End-Use and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Hepcidin (Value)
      • 7.2.1. Global Hepcidin by: Type (Value)
        • 7.2.1.1. DS-79182026
        • 7.2.1.2. M-009
        • 7.2.1.3. PRS-080
        • 7.2.1.4. PTG-300
        • 7.2.1.5. Others
      • 7.2.2. Global Hepcidin by: Application (Value)
        • 7.2.2.1. Acute Inflammation
        • 7.2.2.2. Anemia
        • 7.2.2.3. Iron Deficiency Anemia
        • 7.2.2.4. Sickle Cell Disease
        • 7.2.2.5. Others
      • 7.2.3. Global Hepcidin by: End-Use (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Ambulatory Surgical Centers
        • 7.2.3.3. Diagnostic Centers
        • 7.2.3.4. Specialty Clinics
      • 7.2.4. Global Hepcidin Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hepcidin: by Type(USD Million)
  • Table 2. Hepcidin DS-79182026 , by Region USD Million (2018-2023)
  • Table 3. Hepcidin M-009 , by Region USD Million (2018-2023)
  • Table 4. Hepcidin PRS-080 , by Region USD Million (2018-2023)
  • Table 5. Hepcidin PTG-300 , by Region USD Million (2018-2023)
  • Table 6. Hepcidin Others , by Region USD Million (2018-2023)
  • Table 7. Hepcidin: by Application(USD Million)
  • Table 8. Hepcidin Acute Inflammation , by Region USD Million (2018-2023)
  • Table 9. Hepcidin Anemia , by Region USD Million (2018-2023)
  • Table 10. Hepcidin Iron Deficiency Anemia , by Region USD Million (2018-2023)
  • Table 11. Hepcidin Sickle Cell Disease , by Region USD Million (2018-2023)
  • Table 12. Hepcidin Others , by Region USD Million (2018-2023)
  • Table 13. Hepcidin: by End-Use(USD Million)
  • Table 14. Hepcidin Hospitals , by Region USD Million (2018-2023)
  • Table 15. Hepcidin Ambulatory Surgical Centers , by Region USD Million (2018-2023)
  • Table 16. Hepcidin Diagnostic Centers , by Region USD Million (2018-2023)
  • Table 17. Hepcidin Specialty Clinics , by Region USD Million (2018-2023)
  • Table 18. South America Hepcidin, by Country USD Million (2018-2023)
  • Table 19. South America Hepcidin, by Type USD Million (2018-2023)
  • Table 20. South America Hepcidin, by Application USD Million (2018-2023)
  • Table 21. South America Hepcidin, by End-Use USD Million (2018-2023)
  • Table 22. Brazil Hepcidin, by Type USD Million (2018-2023)
  • Table 23. Brazil Hepcidin, by Application USD Million (2018-2023)
  • Table 24. Brazil Hepcidin, by End-Use USD Million (2018-2023)
  • Table 25. Argentina Hepcidin, by Type USD Million (2018-2023)
  • Table 26. Argentina Hepcidin, by Application USD Million (2018-2023)
  • Table 27. Argentina Hepcidin, by End-Use USD Million (2018-2023)
  • Table 28. Rest of South America Hepcidin, by Type USD Million (2018-2023)
  • Table 29. Rest of South America Hepcidin, by Application USD Million (2018-2023)
  • Table 30. Rest of South America Hepcidin, by End-Use USD Million (2018-2023)
  • Table 31. Asia Pacific Hepcidin, by Country USD Million (2018-2023)
  • Table 32. Asia Pacific Hepcidin, by Type USD Million (2018-2023)
  • Table 33. Asia Pacific Hepcidin, by Application USD Million (2018-2023)
  • Table 34. Asia Pacific Hepcidin, by End-Use USD Million (2018-2023)
  • Table 35. China Hepcidin, by Type USD Million (2018-2023)
  • Table 36. China Hepcidin, by Application USD Million (2018-2023)
  • Table 37. China Hepcidin, by End-Use USD Million (2018-2023)
  • Table 38. Japan Hepcidin, by Type USD Million (2018-2023)
  • Table 39. Japan Hepcidin, by Application USD Million (2018-2023)
  • Table 40. Japan Hepcidin, by End-Use USD Million (2018-2023)
  • Table 41. India Hepcidin, by Type USD Million (2018-2023)
  • Table 42. India Hepcidin, by Application USD Million (2018-2023)
  • Table 43. India Hepcidin, by End-Use USD Million (2018-2023)
  • Table 44. South Korea Hepcidin, by Type USD Million (2018-2023)
  • Table 45. South Korea Hepcidin, by Application USD Million (2018-2023)
  • Table 46. South Korea Hepcidin, by End-Use USD Million (2018-2023)
  • Table 47. Taiwan Hepcidin, by Type USD Million (2018-2023)
  • Table 48. Taiwan Hepcidin, by Application USD Million (2018-2023)
  • Table 49. Taiwan Hepcidin, by End-Use USD Million (2018-2023)
  • Table 50. Australia Hepcidin, by Type USD Million (2018-2023)
  • Table 51. Australia Hepcidin, by Application USD Million (2018-2023)
  • Table 52. Australia Hepcidin, by End-Use USD Million (2018-2023)
  • Table 53. Rest of Asia-Pacific Hepcidin, by Type USD Million (2018-2023)
  • Table 54. Rest of Asia-Pacific Hepcidin, by Application USD Million (2018-2023)
  • Table 55. Rest of Asia-Pacific Hepcidin, by End-Use USD Million (2018-2023)
  • Table 56. Europe Hepcidin, by Country USD Million (2018-2023)
  • Table 57. Europe Hepcidin, by Type USD Million (2018-2023)
  • Table 58. Europe Hepcidin, by Application USD Million (2018-2023)
  • Table 59. Europe Hepcidin, by End-Use USD Million (2018-2023)
  • Table 60. Germany Hepcidin, by Type USD Million (2018-2023)
  • Table 61. Germany Hepcidin, by Application USD Million (2018-2023)
  • Table 62. Germany Hepcidin, by End-Use USD Million (2018-2023)
  • Table 63. France Hepcidin, by Type USD Million (2018-2023)
  • Table 64. France Hepcidin, by Application USD Million (2018-2023)
  • Table 65. France Hepcidin, by End-Use USD Million (2018-2023)
  • Table 66. Italy Hepcidin, by Type USD Million (2018-2023)
  • Table 67. Italy Hepcidin, by Application USD Million (2018-2023)
  • Table 68. Italy Hepcidin, by End-Use USD Million (2018-2023)
  • Table 69. United Kingdom Hepcidin, by Type USD Million (2018-2023)
  • Table 70. United Kingdom Hepcidin, by Application USD Million (2018-2023)
  • Table 71. United Kingdom Hepcidin, by End-Use USD Million (2018-2023)
  • Table 72. Netherlands Hepcidin, by Type USD Million (2018-2023)
  • Table 73. Netherlands Hepcidin, by Application USD Million (2018-2023)
  • Table 74. Netherlands Hepcidin, by End-Use USD Million (2018-2023)
  • Table 75. Rest of Europe Hepcidin, by Type USD Million (2018-2023)
  • Table 76. Rest of Europe Hepcidin, by Application USD Million (2018-2023)
  • Table 77. Rest of Europe Hepcidin, by End-Use USD Million (2018-2023)
  • Table 78. MEA Hepcidin, by Country USD Million (2018-2023)
  • Table 79. MEA Hepcidin, by Type USD Million (2018-2023)
  • Table 80. MEA Hepcidin, by Application USD Million (2018-2023)
  • Table 81. MEA Hepcidin, by End-Use USD Million (2018-2023)
  • Table 82. Middle East Hepcidin, by Type USD Million (2018-2023)
  • Table 83. Middle East Hepcidin, by Application USD Million (2018-2023)
  • Table 84. Middle East Hepcidin, by End-Use USD Million (2018-2023)
  • Table 85. Africa Hepcidin, by Type USD Million (2018-2023)
  • Table 86. Africa Hepcidin, by Application USD Million (2018-2023)
  • Table 87. Africa Hepcidin, by End-Use USD Million (2018-2023)
  • Table 88. North America Hepcidin, by Country USD Million (2018-2023)
  • Table 89. North America Hepcidin, by Type USD Million (2018-2023)
  • Table 90. North America Hepcidin, by Application USD Million (2018-2023)
  • Table 91. North America Hepcidin, by End-Use USD Million (2018-2023)
  • Table 92. United States Hepcidin, by Type USD Million (2018-2023)
  • Table 93. United States Hepcidin, by Application USD Million (2018-2023)
  • Table 94. United States Hepcidin, by End-Use USD Million (2018-2023)
  • Table 95. Canada Hepcidin, by Type USD Million (2018-2023)
  • Table 96. Canada Hepcidin, by Application USD Million (2018-2023)
  • Table 97. Canada Hepcidin, by End-Use USD Million (2018-2023)
  • Table 98. Mexico Hepcidin, by Type USD Million (2018-2023)
  • Table 99. Mexico Hepcidin, by Application USD Million (2018-2023)
  • Table 100. Mexico Hepcidin, by End-Use USD Million (2018-2023)
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Hepcidin: by Type(USD Million)
  • Table 112. Hepcidin DS-79182026 , by Region USD Million (2025-2030)
  • Table 113. Hepcidin M-009 , by Region USD Million (2025-2030)
  • Table 114. Hepcidin PRS-080 , by Region USD Million (2025-2030)
  • Table 115. Hepcidin PTG-300 , by Region USD Million (2025-2030)
  • Table 116. Hepcidin Others , by Region USD Million (2025-2030)
  • Table 117. Hepcidin: by Application(USD Million)
  • Table 118. Hepcidin Acute Inflammation , by Region USD Million (2025-2030)
  • Table 119. Hepcidin Anemia , by Region USD Million (2025-2030)
  • Table 120. Hepcidin Iron Deficiency Anemia , by Region USD Million (2025-2030)
  • Table 121. Hepcidin Sickle Cell Disease , by Region USD Million (2025-2030)
  • Table 122. Hepcidin Others , by Region USD Million (2025-2030)
  • Table 123. Hepcidin: by End-Use(USD Million)
  • Table 124. Hepcidin Hospitals , by Region USD Million (2025-2030)
  • Table 125. Hepcidin Ambulatory Surgical Centers , by Region USD Million (2025-2030)
  • Table 126. Hepcidin Diagnostic Centers , by Region USD Million (2025-2030)
  • Table 127. Hepcidin Specialty Clinics , by Region USD Million (2025-2030)
  • Table 128. South America Hepcidin, by Country USD Million (2025-2030)
  • Table 129. South America Hepcidin, by Type USD Million (2025-2030)
  • Table 130. South America Hepcidin, by Application USD Million (2025-2030)
  • Table 131. South America Hepcidin, by End-Use USD Million (2025-2030)
  • Table 132. Brazil Hepcidin, by Type USD Million (2025-2030)
  • Table 133. Brazil Hepcidin, by Application USD Million (2025-2030)
  • Table 134. Brazil Hepcidin, by End-Use USD Million (2025-2030)
  • Table 135. Argentina Hepcidin, by Type USD Million (2025-2030)
  • Table 136. Argentina Hepcidin, by Application USD Million (2025-2030)
  • Table 137. Argentina Hepcidin, by End-Use USD Million (2025-2030)
  • Table 138. Rest of South America Hepcidin, by Type USD Million (2025-2030)
  • Table 139. Rest of South America Hepcidin, by Application USD Million (2025-2030)
  • Table 140. Rest of South America Hepcidin, by End-Use USD Million (2025-2030)
  • Table 141. Asia Pacific Hepcidin, by Country USD Million (2025-2030)
  • Table 142. Asia Pacific Hepcidin, by Type USD Million (2025-2030)
  • Table 143. Asia Pacific Hepcidin, by Application USD Million (2025-2030)
  • Table 144. Asia Pacific Hepcidin, by End-Use USD Million (2025-2030)
  • Table 145. China Hepcidin, by Type USD Million (2025-2030)
  • Table 146. China Hepcidin, by Application USD Million (2025-2030)
  • Table 147. China Hepcidin, by End-Use USD Million (2025-2030)
  • Table 148. Japan Hepcidin, by Type USD Million (2025-2030)
  • Table 149. Japan Hepcidin, by Application USD Million (2025-2030)
  • Table 150. Japan Hepcidin, by End-Use USD Million (2025-2030)
  • Table 151. India Hepcidin, by Type USD Million (2025-2030)
  • Table 152. India Hepcidin, by Application USD Million (2025-2030)
  • Table 153. India Hepcidin, by End-Use USD Million (2025-2030)
  • Table 154. South Korea Hepcidin, by Type USD Million (2025-2030)
  • Table 155. South Korea Hepcidin, by Application USD Million (2025-2030)
  • Table 156. South Korea Hepcidin, by End-Use USD Million (2025-2030)
  • Table 157. Taiwan Hepcidin, by Type USD Million (2025-2030)
  • Table 158. Taiwan Hepcidin, by Application USD Million (2025-2030)
  • Table 159. Taiwan Hepcidin, by End-Use USD Million (2025-2030)
  • Table 160. Australia Hepcidin, by Type USD Million (2025-2030)
  • Table 161. Australia Hepcidin, by Application USD Million (2025-2030)
  • Table 162. Australia Hepcidin, by End-Use USD Million (2025-2030)
  • Table 163. Rest of Asia-Pacific Hepcidin, by Type USD Million (2025-2030)
  • Table 164. Rest of Asia-Pacific Hepcidin, by Application USD Million (2025-2030)
  • Table 165. Rest of Asia-Pacific Hepcidin, by End-Use USD Million (2025-2030)
  • Table 166. Europe Hepcidin, by Country USD Million (2025-2030)
  • Table 167. Europe Hepcidin, by Type USD Million (2025-2030)
  • Table 168. Europe Hepcidin, by Application USD Million (2025-2030)
  • Table 169. Europe Hepcidin, by End-Use USD Million (2025-2030)
  • Table 170. Germany Hepcidin, by Type USD Million (2025-2030)
  • Table 171. Germany Hepcidin, by Application USD Million (2025-2030)
  • Table 172. Germany Hepcidin, by End-Use USD Million (2025-2030)
  • Table 173. France Hepcidin, by Type USD Million (2025-2030)
  • Table 174. France Hepcidin, by Application USD Million (2025-2030)
  • Table 175. France Hepcidin, by End-Use USD Million (2025-2030)
  • Table 176. Italy Hepcidin, by Type USD Million (2025-2030)
  • Table 177. Italy Hepcidin, by Application USD Million (2025-2030)
  • Table 178. Italy Hepcidin, by End-Use USD Million (2025-2030)
  • Table 179. United Kingdom Hepcidin, by Type USD Million (2025-2030)
  • Table 180. United Kingdom Hepcidin, by Application USD Million (2025-2030)
  • Table 181. United Kingdom Hepcidin, by End-Use USD Million (2025-2030)
  • Table 182. Netherlands Hepcidin, by Type USD Million (2025-2030)
  • Table 183. Netherlands Hepcidin, by Application USD Million (2025-2030)
  • Table 184. Netherlands Hepcidin, by End-Use USD Million (2025-2030)
  • Table 185. Rest of Europe Hepcidin, by Type USD Million (2025-2030)
  • Table 186. Rest of Europe Hepcidin, by Application USD Million (2025-2030)
  • Table 187. Rest of Europe Hepcidin, by End-Use USD Million (2025-2030)
  • Table 188. MEA Hepcidin, by Country USD Million (2025-2030)
  • Table 189. MEA Hepcidin, by Type USD Million (2025-2030)
  • Table 190. MEA Hepcidin, by Application USD Million (2025-2030)
  • Table 191. MEA Hepcidin, by End-Use USD Million (2025-2030)
  • Table 192. Middle East Hepcidin, by Type USD Million (2025-2030)
  • Table 193. Middle East Hepcidin, by Application USD Million (2025-2030)
  • Table 194. Middle East Hepcidin, by End-Use USD Million (2025-2030)
  • Table 195. Africa Hepcidin, by Type USD Million (2025-2030)
  • Table 196. Africa Hepcidin, by Application USD Million (2025-2030)
  • Table 197. Africa Hepcidin, by End-Use USD Million (2025-2030)
  • Table 198. North America Hepcidin, by Country USD Million (2025-2030)
  • Table 199. North America Hepcidin, by Type USD Million (2025-2030)
  • Table 200. North America Hepcidin, by Application USD Million (2025-2030)
  • Table 201. North America Hepcidin, by End-Use USD Million (2025-2030)
  • Table 202. United States Hepcidin, by Type USD Million (2025-2030)
  • Table 203. United States Hepcidin, by Application USD Million (2025-2030)
  • Table 204. United States Hepcidin, by End-Use USD Million (2025-2030)
  • Table 205. Canada Hepcidin, by Type USD Million (2025-2030)
  • Table 206. Canada Hepcidin, by Application USD Million (2025-2030)
  • Table 207. Canada Hepcidin, by End-Use USD Million (2025-2030)
  • Table 208. Mexico Hepcidin, by Type USD Million (2025-2030)
  • Table 209. Mexico Hepcidin, by Application USD Million (2025-2030)
  • Table 210. Mexico Hepcidin, by End-Use USD Million (2025-2030)
  • Table 211. Research Programs/Design for This Report
  • Table 212. Key Data Information from Secondary Sources
  • Table 213. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hepcidin: by Type USD Million (2018-2023)
  • Figure 5. Global Hepcidin: by Application USD Million (2018-2023)
  • Figure 6. Global Hepcidin: by End-Use USD Million (2018-2023)
  • Figure 7. South America Hepcidin Share (%), by Country
  • Figure 8. Asia Pacific Hepcidin Share (%), by Country
  • Figure 9. Europe Hepcidin Share (%), by Country
  • Figure 10. MEA Hepcidin Share (%), by Country
  • Figure 11. North America Hepcidin Share (%), by Country
  • Figure 12. Global Hepcidin share by Players 2023 (%)
  • Figure 13. Global Hepcidin share by Players (Top 3) 2023(%)
  • Figure 14. Global Hepcidin share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Allergen PLC (Ireland) Revenue, Net Income and Gross profit
  • Figure 17. Allergen PLC (Ireland) Revenue: by Geography 2023
  • Figure 18. AMAG Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. AMAG Pharmaceuticals Inc. (United States) Revenue: by Geography 2023
  • Figure 20. Keryx Biopharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Keryx Biopharmaceuticals Inc. (United States) Revenue: by Geography 2023
  • Figure 22. Luitpold Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Luitpold Pharmaceuticals Inc. (United States) Revenue: by Geography 2023
  • Figure 24. Pieris Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Pieris Pharmaceuticals Inc. (United States) Revenue: by Geography 2023
  • Figure 26. Sanofi Aventis (France) Revenue, Net Income and Gross profit
  • Figure 27. Sanofi Aventis (France) Revenue: by Geography 2023
  • Figure 28. Janssen Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Janssen Pharmaceuticals, Inc. (United States) Revenue: by Geography 2023
  • Figure 30. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 32. Rockwell Medical (United States) Revenue, Net Income and Gross profit
  • Figure 33. Rockwell Medical (United States) Revenue: by Geography 2023
  • Figure 34. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 35. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2023
  • Figure 36. Global Hepcidin: by Type USD Million (2025-2030)
  • Figure 37. Global Hepcidin: by Application USD Million (2025-2030)
  • Figure 38. Global Hepcidin: by End-Use USD Million (2025-2030)
  • Figure 39. South America Hepcidin Share (%), by Country
  • Figure 40. Asia Pacific Hepcidin Share (%), by Country
  • Figure 41. Europe Hepcidin Share (%), by Country
  • Figure 42. MEA Hepcidin Share (%), by Country
  • Figure 43. North America Hepcidin Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Allergen PLC (Ireland)
  • AMAG Pharmaceuticals Inc. (United States)
  • Keryx Biopharmaceuticals Inc. (United States)
  • Luitpold Pharmaceuticals Inc. (United States)
  • Pieris Pharmaceuticals Inc. (United States)
  • Sanofi Aventis (France)
  • Janssen Pharmaceuticals, Inc. (United States)
  • Pfizer Inc. (United States)
  • Rockwell Medical (United States)
  • F. Hoffmann-La Roche Ltd (Switzerland)
Additional players considered in the study are as follows:
Akebia Therapeutics Inc. (United States) , Sandoz international gmbh (Germany) , Pharmacosmos AS (Denmark)
Select User Access Type

Key Highlights of Report


Mar 2024 233 Pages 74 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Hepcidin Quantitative research analysis
Global Hepcidin Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2018-2023; Base year: 2023; Forecast period: 2024 to 2030
Companies that are profiled in Global Hepcidin Market are Allergen PLC (Ireland), AMAG Pharmaceuticals Inc. (United States), Keryx Biopharmaceuticals Inc. (United States), Luitpold Pharmaceuticals Inc. (United States), Pieris Pharmaceuticals Inc. (United States), Sanofi Aventis (France), Janssen Pharmaceuticals, Inc. (United States), Pfizer Inc. (United States), Rockwell Medical (United States) and F. Hoffmann-La Roche Ltd (Switzerland) etc.
Acute Inflammation segment in Global market to hold robust market share owing to "Rising the Incidence of Anemia ".
AMA Research predicts that United States Players will contribute to the maximum growth of Global Hepcidin market throughout the forecasted period.

Know More About Global Hepcidin Report?

Have a Query? Click Here

Other Related Reports

Stem Cell Antibody Comprehensive Study by Type (Primary Antibodies, Secondary Antibodies), Application (Developmental biology, Disease modeling research, Drug development screening, Cell therapy stud...
$ 3750
Transfection Reagents Comprehensive Study by Type (Reagents, Instruments), Application (Biomedical Research, Gene Expression Studies, Cancer Research, Transgenic Model, Protein Production, Therapeuti...
$ 3750
Radiopharmaceuticals in Nuclear Medicine Comprehensive Study by Type (Diagnostic Nuclear Medicine (PECT Radiopharmaceuticals, PET Radiopharmaceuticals), Therapeutic Nuclear Medicine (Alpha Emitters, ...
$ 3750
Cosmetic Implants Comprehensive Study by Type (Breast Implants, Dental Implants, Facial Implants, Others), Application (Hospital, Cosmetic Club), Material (Polymers, Metal Implants, Bio Material, Cer...
$ 3500
Slide Stainer Comprehensive Study by Type (Reagent, Equipment {Automated, Manual}, Consumables & Accessories), End User (Hospitals and Diagnostic Laboratories, Academic and Research Institutes, Phar...
$ 3750
Microbial Products Comprehensive Study by Type (Enzymes, Polysaccharides, Nutrients ( (Amino Acids, Nucleotides, Vitamins, And Organic Acids), Chemotherapeutic Agents, Vaccines, Antibiotics, Others),...
$ 3750